A novel DMTN :: HMGA2 rearrangement drives aberrant reactivation of HMGA2 with profibrotic and type I interferon–suppressive signaling
Background HMGA2 dysregulation has been implicated in myeloid neoplasms, but its contribution to MPN pathogenesis remains to be fully understood.Methods We identified and characterized a rare DMTN:HMGA2 rearrangement using mate-pair whole-genome rearrangement sequencing in a patient with post-Essential Thrombocythemia myelofibrosis. We then investigated the functional consequences of aberrant reactivation of HMGA2 using HMGA2-overexpressing Ba/F3 and 32D hematopoietic cell models, followed by transcriptomic and functional analyzes. Finally, HMGA2-associated transcriptional programs were evaluated in clinical MPN cohorts.Results The DMTN:HMGA2 rearrangement involved the 5′UTR of DMTN and the 3′UTR of HMGA2 without generating a chimeric coding transcript, but was associated with aberrant HMGA2 activation. HMGA2 overexpression in hematopoietic cells in vitro induced a proinflammatory, profibrotic, prothrombotic, and proangiogenic transcriptional program, with upregulation of Il6, P2rx7, Ccr1, Thbs3, Sned1, Serpine1, Pgf, and Angptl2. Conversely, 121 commonly downregulated genes were enriched for type I interferon-related programs, including Ifi44, Ifit1, Oas family genes, Isg15, Irf7, Zbp1, and Mx1/2. Functionally, HMGA2 overexpression reduced IFN-α-induced STAT1/STAT2 phosphorylation, decreased IFN-α-induced apoptosis, and preserved cell proliferation following IFN-α treatment. In two independent clinical MPN cohorts, higher HMGA2 expression was consistently associated with lower activity of type I interferon and other immune-related pathways, as well as higher activity of selected mesenchymal- and stromal-related pathways.Conclusion Our findings suggest that aberrant HMGA2 reactivation can promote an inflammatory, profibrotic, and IFN-suppressive state in hematopoietic cells, providing a potential mechanistic link between HMGA2 dysregulation and MPN biology.
Authors
- Jintao Xu (ORCID: https://orcid.org/0000-0002-9946-8601)
- Xingping Lang
- Sujuan Zhou
- Yan Lin (ORCID: https://orcid.org/0000-0003-4956-861X)
- Nan Chen (ORCID: https://orcid.org/0000-0002-0822-125X)
- Fan Yang (ORCID: https://orcid.org/0000-0002-0411-7391)
- Sheng Xiao (ORCID: https://orcid.org/0000-0001-8852-6434)
- Mei Yang
- Lijun Meng (ORCID: https://orcid.org/0009-0002-9442-2767)
- Shouli Wang
- Liying Zhang (ORCID: https://orcid.org/0000-0002-8890-2484)
Institutions
- Soochow University (CN)
- Affiliated Hospital of Nantong University (CN)
- The First People's Hospital of Changzhou (CN)
- Second Affiliated Hospital of Soochow University (CN)
Publication Details
- Journal
- Cancer Biology & Therapy
- Published
- 2026-11-18
- DOI
- https://doi.org/10.1080/15384047.2026.2758577
- Primary Topic
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Government of Jiangsu Province